Skip to main content
Top
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells

Authors: Guoqiang Chang, Hongju Zhang, Jian Wang, Yujuan Zhang, Hua Xu, Chijuan Wang, Hairui Zhang, Li Ma, Qinghua Li, Tianxiang Pang

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Chronic myeloid leukemia is a clonal myeloproliferative disorder disease in which BCR/ABL plays an important role as an oncoprotein and molecular target. Despite the success of targeted therapy using tyrosine kinase inhibitors, CML remains largely incurable, most likely due to the treatment resistance after firstly chemical therapy. So know well the unique molecular pathway of CML is very important.

Methods

The expressions of CD44 in different leukemia patients and cell lines were detected by real-time PCR and western blotting. The effects of CD44 on proliferation of K562 cells were determined using the MTT and colony formation assays, and even in a nude mouse transplantation model. Then, the cell cycle changes were detected by flow cytometric analysis and the early apoptosis of cells was detected by the annexin V/propidium iodide double-staining assay. The expressions of the cycles and apoptosis-related proteins p21, Cyclin D1 and Bcl-2 were analyzed by western blot and real-time PCR assay. Finally, the decreased nuclear accumulation of β-catenin was detected by western blotting and immunefluorescence.

Results

Firstly, we showed that CD44 expression was increased in several kinds of leukemia patients and K562 cells. By contrast, the down-regulation of CD44 resulted in decreased proliferation with a G0/G1 arrest of cell cycle in K562 cells according to the MTT assay and the flow cytometric analysis. And no significant induction of both the early and late phases of apoptosis was shown by the annexin V-FITC and PI staining. During this process, p21 and cyclin D1 are the major causes for cell cycle arrest. In addition, we found CD44 down-regulation decreased the expression of β-catenin and increased the expression of phosphorylated β-catenin. The instability of Wnt/β-catenin pathway induced by increased expression of p-β-catenin resulted in a decreased nuclear accumulation in CD44 silenced K562 cells. In the nude mouse transplantation model, we also found the same results.

Conclusions

These results show that K562 cells depend to a greater extent on CD44 for proliferation, and CD44 down-regulation may induce a cell cycle arrest through Wnt/β-catenin pathway. CD44 blockade may be beneficial in therapy of CML.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chen Y, Peng C, Sullivan C, Li D, Li S: Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010, 24 (9): 1545-1554. 10.1038/leu.2010.143.PubMedCentralCrossRefPubMed Chen Y, Peng C, Sullivan C, Li D, Li S: Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010, 24 (9): 1545-1554. 10.1038/leu.2010.143.PubMedCentralCrossRefPubMed
2.
go back to reference Hochhaus A, La Rosee P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004, 18 (8): 1321-1331. 10.1038/sj.leu.2403426.CrossRefPubMed Hochhaus A, La Rosee P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004, 18 (8): 1321-1331. 10.1038/sj.leu.2403426.CrossRefPubMed
3.
go back to reference Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T: Chronic myelogenous leukemia molecular signature. Oncogene. 2003, 22 (25): 3952-3963. 10.1038/sj.onc.1206620.CrossRefPubMed Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T: Chronic myelogenous leukemia molecular signature. Oncogene. 2003, 22 (25): 3952-3963. 10.1038/sj.onc.1206620.CrossRefPubMed
4.
go back to reference Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004, 351 (7): 657-667. 10.1056/NEJMoa040258.CrossRefPubMed Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004, 351 (7): 657-667. 10.1056/NEJMoa040258.CrossRefPubMed
5.
go back to reference Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S: Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice. Proc Natl Acad Sci U S A. 2006, 103 (45): 16870-16875. 10.1073/pnas.0606509103.PubMedCentralCrossRefPubMed Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S: Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice. Proc Natl Acad Sci U S A. 2006, 103 (45): 16870-16875. 10.1073/pnas.0606509103.PubMedCentralCrossRefPubMed
6.
go back to reference Hu Y, Chen Y, Douglas L, Li S: Beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009, 23 (1): 109-116. 10.1038/leu.2008.262.CrossRefPubMed Hu Y, Chen Y, Douglas L, Li S: Beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009, 23 (1): 109-116. 10.1038/leu.2008.262.CrossRefPubMed
7.
go back to reference Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E: Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer. 2012, 106 (5): 846-853. 10.1038/bjc.2012.33.PubMedCentralCrossRefPubMed Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E: Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer. 2012, 106 (5): 846-853. 10.1038/bjc.2012.33.PubMedCentralCrossRefPubMed
8.
go back to reference Trapasso S, Allegra E: Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biol: Targets Ther. 2012, 6: 379-383. Trapasso S, Allegra E: Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biol: Targets Ther. 2012, 6: 379-383.
9.
go back to reference Krause DS, Lazarides K, von Andrian UH, Van Etten RA: Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006, 12 (10): 1175-1180. 10.1038/nm1489.CrossRefPubMed Krause DS, Lazarides K, von Andrian UH, Van Etten RA: Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006, 12 (10): 1175-1180. 10.1038/nm1489.CrossRefPubMed
10.
go back to reference Liu P, Wakamiya M, Shea MJ, Albrecht U, Behringer RR, Bradley A: Requirement for Wnt3 in vertebrate axis formation. Nat Gen. 1999, 22 (4): 361-365. 10.1038/11932.CrossRef Liu P, Wakamiya M, Shea MJ, Albrecht U, Behringer RR, Bradley A: Requirement for Wnt3 in vertebrate axis formation. Nat Gen. 1999, 22 (4): 361-365. 10.1038/11932.CrossRef
11.
go back to reference Miller C, Sassoon DA: Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development. 1998, 125 (16): 3201-3211.PubMed Miller C, Sassoon DA: Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development. 1998, 125 (16): 3201-3211.PubMed
12.
go back to reference Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007, 12 (6): 528-541. 10.1016/j.ccr.2007.11.003.PubMedCentralCrossRefPubMed Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007, 12 (6): 528-541. 10.1016/j.ccr.2007.11.003.PubMedCentralCrossRefPubMed
13.
go back to reference Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA: The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010, 327 (5973): 1650-1653. 10.1126/science.1186624.PubMedCentralCrossRefPubMed Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA: The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010, 327 (5973): 1650-1653. 10.1126/science.1186624.PubMedCentralCrossRefPubMed
14.
go back to reference Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, Mansat-De Mas V, Rigal-Huguet F, Laurent G, Payrastre B: Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006, 20 (7): 1211-1216. 10.1038/sj.leu.2404239.CrossRefPubMed Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, Mansat-De Mas V, Rigal-Huguet F, Laurent G, Payrastre B: Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006, 20 (7): 1211-1216. 10.1038/sj.leu.2404239.CrossRefPubMed
15.
go back to reference Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004, 101 (9): 3118-3123. 10.1073/pnas.0308648100.PubMedCentralCrossRefPubMed Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004, 101 (9): 3118-3123. 10.1073/pnas.0308648100.PubMedCentralCrossRefPubMed
16.
go back to reference Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127 (3): 469-480. 10.1016/j.cell.2006.10.018.CrossRefPubMed Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127 (3): 469-480. 10.1016/j.cell.2006.10.018.CrossRefPubMed
17.
go back to reference Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Cheli Y: Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J Mol Cell Biol. 2012, 4 (4): 207-220. 10.1093/jmcb/mjs010.CrossRefPubMed Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Cheli Y: Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J Mol Cell Biol. 2012, 4 (4): 207-220. 10.1093/jmcb/mjs010.CrossRefPubMed
18.
go back to reference Cortes J, Kantarjian H: How I treat newly diagnosed chronic phase CML. Blood. 2012, 120 (7): 1390-1397. 10.1182/blood-2012-03-378919.CrossRefPubMed Cortes J, Kantarjian H: How I treat newly diagnosed chronic phase CML. Blood. 2012, 120 (7): 1390-1397. 10.1182/blood-2012-03-378919.CrossRefPubMed
19.
go back to reference Wei G, Rafiyath S, Liu D: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010, 3: 47-10.1186/1756-8722-3-47.PubMedCentralCrossRefPubMed Wei G, Rafiyath S, Liu D: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010, 3: 47-10.1186/1756-8722-3-47.PubMedCentralCrossRefPubMed
20.
go back to reference Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG: BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011, 4: 6-10.1186/1756-8722-4-6.PubMedCentralCrossRefPubMed Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG: BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011, 4: 6-10.1186/1756-8722-4-6.PubMedCentralCrossRefPubMed
21.
go back to reference Sloma I, Jiang X, Eaves AC, Eaves CJ: Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010, 24 (11): 1823-1833. 10.1038/leu.2010.159.CrossRefPubMed Sloma I, Jiang X, Eaves AC, Eaves CJ: Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010, 24 (11): 1823-1833. 10.1038/leu.2010.159.CrossRefPubMed
22.
go back to reference Deininger M: Hematology: curing CML with imatinib–a dream come true?. Nat Rev Clin Oncol. 2011, 8 (3): 127-128. 10.1038/nrclinonc.2011.17.CrossRefPubMed Deininger M: Hematology: curing CML with imatinib–a dream come true?. Nat Rev Clin Oncol. 2011, 8 (3): 127-128. 10.1038/nrclinonc.2011.17.CrossRefPubMed
23.
go back to reference Ghosh SC, Neslihan Alpay S, Klostergaard J: CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets. 2012, 16 (7): 635-650. 10.1517/14728222.2012.687374.CrossRefPubMed Ghosh SC, Neslihan Alpay S, Klostergaard J: CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets. 2012, 16 (7): 635-650. 10.1517/14728222.2012.687374.CrossRefPubMed
24.
go back to reference Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK: Role of CD44 in tumour progression and strategies for targeting. J Drug Target. 2012, 20 (7): 561-573. 10.3109/1061186X.2012.702767.CrossRefPubMed Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK: Role of CD44 in tumour progression and strategies for targeting. J Drug Target. 2012, 20 (7): 561-573. 10.3109/1061186X.2012.702767.CrossRefPubMed
25.
go back to reference Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006, 12 (10): 1167-1174. 10.1038/nm1483.CrossRefPubMed Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006, 12 (10): 1167-1174. 10.1038/nm1483.CrossRefPubMed
26.
go back to reference Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS: Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7 (6): e1000121-10.1371/journal.pbio.1000121.PubMedCentralCrossRefPubMed Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS: Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7 (6): e1000121-10.1371/journal.pbio.1000121.PubMedCentralCrossRefPubMed
27.
go back to reference Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP: The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer. 2010, 9: 212-10.1186/1476-4598-9-212.PubMedCentralCrossRefPubMed Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP: The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer. 2010, 9: 212-10.1186/1476-4598-9-212.PubMedCentralCrossRefPubMed
28.
go back to reference Clevers H, Nusse R: Wnt/beta-catenin signaling and disease. Cell. 2012, 149 (6): 1192-1205. 10.1016/j.cell.2012.05.012.CrossRefPubMed Clevers H, Nusse R: Wnt/beta-catenin signaling and disease. Cell. 2012, 149 (6): 1192-1205. 10.1016/j.cell.2012.05.012.CrossRefPubMed
29.
go back to reference MacDonald BT, Tamai K, He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009, 17 (1): 9-26. 10.1016/j.devcel.2009.06.016.PubMedCentralCrossRefPubMed MacDonald BT, Tamai K, He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009, 17 (1): 9-26. 10.1016/j.devcel.2009.06.016.PubMedCentralCrossRefPubMed
30.
go back to reference Sarkar S, Swiercz R, Kantara C, Hajjar KA, Singh P: Annexin A2 mediates up-regulation of NF-kappaB, beta-catenin, and stem cell in response to progastrin in mice and HEK-293 cells. Gastroenterology. 2011, 140 (2): 583-595. 10.1053/j.gastro.2010.08.054. e584PubMedCentralCrossRefPubMed Sarkar S, Swiercz R, Kantara C, Hajjar KA, Singh P: Annexin A2 mediates up-regulation of NF-kappaB, beta-catenin, and stem cell in response to progastrin in mice and HEK-293 cells. Gastroenterology. 2011, 140 (2): 583-595. 10.1053/j.gastro.2010.08.054. e584PubMedCentralCrossRefPubMed
31.
go back to reference Han J, Gao B, Jin X, Xu Z, Li Z, Sun Y, Song B: Small interfering RNA-mediated downregulation of beta-catenin inhibits invasion and migration of colon cancer cells in vitro. Med Sci Monit. 2012, 18 (7): BR273-BR280.PubMedCentralCrossRefPubMed Han J, Gao B, Jin X, Xu Z, Li Z, Sun Y, Song B: Small interfering RNA-mediated downregulation of beta-catenin inhibits invasion and migration of colon cancer cells in vitro. Med Sci Monit. 2012, 18 (7): BR273-BR280.PubMedCentralCrossRefPubMed
32.
go back to reference Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST: Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999, 154 (2): 515-523. 10.1016/S0002-9440(10)65297-2.PubMedCentralCrossRefPubMed Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST: Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999, 154 (2): 515-523. 10.1016/S0002-9440(10)65297-2.PubMedCentralCrossRefPubMed
33.
go back to reference Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M: Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2013, in press Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M: Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2013, in press
34.
go back to reference Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, Banerjee S: Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia. 2007, 21 (5): 949-955.PubMed Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, Banerjee S: Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia. 2007, 21 (5): 949-955.PubMed
35.
go back to reference Weinberg WC, Denning MF: P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med. 2002, 13 (6): 453-464. 10.1177/154411130201300603.CrossRefPubMed Weinberg WC, Denning MF: P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med. 2002, 13 (6): 453-464. 10.1177/154411130201300603.CrossRefPubMed
36.
go back to reference Romanov VS, Pospelov VA, Pospelova TV: Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochem Biokhimiia. 2012, 77 (6): 575-584. 10.1134/S000629791206003X.CrossRef Romanov VS, Pospelov VA, Pospelova TV: Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochem Biokhimiia. 2012, 77 (6): 575-584. 10.1134/S000629791206003X.CrossRef
37.
go back to reference Jirawatnotai S, Hu Y, Livingston DM, Sicinski P: Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res. 2012, 72 (17): 4289-4293. 10.1158/0008-5472.CAN-11-3549.PubMedCentralCrossRefPubMed Jirawatnotai S, Hu Y, Livingston DM, Sicinski P: Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res. 2012, 72 (17): 4289-4293. 10.1158/0008-5472.CAN-11-3549.PubMedCentralCrossRefPubMed
38.
go back to reference Ashrafi M, Bathaie SZ, Abroun S: High Expression of Cyclin D1 and p21 in N-Nitroso-N-Methylurea-Induced Breast Cancer in Wistar Albino Female Rats. Cell J. 2012, 14 (3): 193-202.PubMedCentralPubMed Ashrafi M, Bathaie SZ, Abroun S: High Expression of Cyclin D1 and p21 in N-Nitroso-N-Methylurea-Induced Breast Cancer in Wistar Albino Female Rats. Cell J. 2012, 14 (3): 193-202.PubMedCentralPubMed
39.
go back to reference Ekholm SV, Reed SI: Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000, 12 (6): 676-684. 10.1016/S0955-0674(00)00151-4.CrossRefPubMed Ekholm SV, Reed SI: Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000, 12 (6): 676-684. 10.1016/S0955-0674(00)00151-4.CrossRefPubMed
40.
go back to reference Wang L, Li H, Wang J, Gao W, Lin Y, Jin W, Chang G, Wang R, Li Q, Ma L: C/EBP zeta targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells. Biochim Biophys Acta. 2011, 1813 (10): 1803-1813. 10.1016/j.bbamcr.2011.06.010.CrossRefPubMed Wang L, Li H, Wang J, Gao W, Lin Y, Jin W, Chang G, Wang R, Li Q, Ma L: C/EBP zeta targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells. Biochim Biophys Acta. 2011, 1813 (10): 1803-1813. 10.1016/j.bbamcr.2011.06.010.CrossRefPubMed
Metadata
Title
CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells
Authors
Guoqiang Chang
Hongju Zhang
Jian Wang
Yujuan Zhang
Hua Xu
Chijuan Wang
Hairui Zhang
Li Ma
Qinghua Li
Tianxiang Pang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-117

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine